title: Risks and benefits of splenectomy in myelofibrosis with myeloid metaplasia: a retrospective analysis of 26 cases.
abstract: OBJECTIVE
  To evaluate the outcomes of splenectomy in myelofibrosis and myeloid metaplasia (MMM).
  
  
  METHODS
  We retrospectively reviewed our records of 26 patients with MMM who underwent an open splenectomy at Boston University Medical Center between 1979 and 1995. Fourteen patients had agnogenic myeloid metaplasia (AMM) and 12 had myelofibrosis with antecedent myeloproliferative disorders (MF). The main indications for splenectomy were progressive transfusion-dependent anemia, painful splenomegaly, and hypercatabolic symptoms associated with cytopenia.
  
  
  RESULTS
  Median time to splenectomy after the diagnosis of MMM was 29 months ranging from 1 to 96 months. Three patients (11%) died within 1 month after the surgery because of sepsis. The most common peri- and postoperative complications were pneumonia and other bacterial infections (42%), cardiac events (19%), acute bleeding (15%), ileus (15%), and venous thrombosis (12%). Of the eight surviving patients who underwent splenectomy for transfusion dependent anemia, six (75%) had improvement in their hematocrit levels with abolishment of blood transfusions. A durable symptomatic palliation was achieved in all patients. Liver enlargement was noted in seven patients at 1-year evaluation. None of these patients developed hepatic failure. Leukemic transformation occurred in 8 of 18 patients (44%) postsplenectomy. The median overall survival for the entire group was 58.5 and 28 months from the diagnosis of MMM and the time of splenectomy, respectively. There was no difference in survival rates between patients with AMM and MF.
  
  
  CONCLUSIONS
  Splenectomy is an effective palliative procedure with an acceptable morbidity in selected patients with MMM. Progressive transfusion-dependent anemia should also be considered an indication for splenectomy in the absence of leukemic evolution.
authors.affiliation: Section of Hematology and Oncology in the Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA. gakpek@jhmi.edu
authors.forename: G
authors.initials: G
authors.lastname: Akpek
authors.forename: D
authors.initials: D
authors.lastname: McAneny
authors.forename: L
authors.initials: L
authors.lastname: Weintraub
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010166:Palliative Care; D055728:Primary Myelofibrosis / Q000150:complications* / Q000601:surgery*; D012189:Retrospective Studies; D012306:Risk; D013156:Splenectomy / Q000401:mortality; D013163:Splenomegaly / Q000150:complications; D016019:Survival Analysis; D016896:Treatment Outcome